OYC Americas is pleased to announce availability of highly-qualified, fully physiologically-active β-nicotinamide mononucleotide (NMN) for laboratory research applications in academia and pharmaceuticals.
Recent studies have publicized this coenzyme as a potential key anti-aging factor, with initial results in mice showing exciting implications for age-related diseases such as diabetes, neurodegenerative disorders, and cardiac disease.
These studies demonstrated improvement in diet-induced glucose intolerance, restoration of age-related mitochondrial dysfunction, reduction of infarct area in response to ischemia/reperfusion, and a rescue effect for age-related decline in neural stem cells.
Given the revenue-generation potential for effective anti-aging medications, and given the upswing in diabetes throughout the population, the NMN coenzyme is in high demand for research studies in laboratories across the United States.